MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Predictive factors of LCIG infusion therapy adherence – a single-center study of 103 consecutive LCIG patients

    V. Viljaharju, T. Mertsalmi, KAM. Pauls, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

    Objective: The objectives of this study were to find predictive factors for early dropout from levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD)…
  • MDS Virtual Congress 2021

    Levodopa responsive gait dynamics in ON- and OFF-state freezing of gait in Parkinson’s disease

    T. Virmani, L. Pillai, A. Glover, R. Landes (Little Rock, USA)

    Objective: To determine which spatiotemporal gait parameters respond to levodopa in Parkinson’s patients with levodopa ON- and OFF-state gait freezing. Background: Levodopa-ON-state gait freezing is…
  • MDS Virtual Congress 2021

    The responsiveness of arm swing to dopaminergic medication in Parkinson’s disease depends on task complexity

    E. Warmerdam, R. Romijnders, C. Hansen, M. Elshehabi, M. Zimmermann, F. Metzger, A. von Thaler, D. Berg, G. Schmidt, W. Maetzler (Kiel, Germany)

    Objective: The aim of this study is to analyse the responsiveness of arm swing during walking to dopaminergic medication in patients with Parkinson’s disease. Background:…
  • MDS Virtual Congress 2021

    Safinamide Improves Pain in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

    R. Yáñez, C. Labandeira, M. Cimas Hernando, I. Cabo, J. Paz González, M. Alonso Losada, M. González Palmás, C. Martínez, D. Santos García (Ourense, Spain)

    Objective: Our aim was to analyze the effectiveness of safinamide on pain in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…
  • MDS Virtual Congress 2021

    Comparison and analysis of pupillometer parameters between patients with drug naive Parkinson’s disease and controls

    S. You, J. Yoo (Daegu, Republic of Korea)

    Objective: We compared the pupillary findings of drug-naïve Parkinson’s disease (PD) patients and controls to investigate the characteristics of pupillary light reflexes (PLR) in PD…
  • MDS Virtual Congress 2021

    Electroconvulsive therapy for refractory psychiatric symptoms in GBA-related Parkinson disease patient

    JY. Yun, EH. Lee (Seoul, Republic of Korea)

    Objective: This case report aims to highlight the ECT as a promising option on refractory neuropsychiatric manifestations of PD. Background: In GBA-related PD, non-motor symptoms…
  • MDS Virtual Congress 2021

    Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson’s disease

    JB. Zhang, C. Ren, KJ. He, F. Wang, CF. Liu (Suzhou, China)

    Objective: The aim of this study is to explore whether the inhibition of GluN2D-containing NMDA receptors (NMDAR2D) can delay the pathological manifestations of Parkinson's disease…
  • MDS Virtual Congress 2021

    Improved Excessive Daytime Sleepiness with Selegiline in patients with Parkinson’s Disease: An Open Trial

    JR. Zhang, JP. Chen, J. Li, J. Li, CJ. Mao, CF. Liu (Suzhou, China)

    Objective: This study, an open-labeled trial, was aimed to assess the efficacy and safety of selegiline on the treatment of EDS in PD patients. Background: Excessive Daytime…
  • MDS Virtual Congress 2021

    Unraveling the mechanisms of Tubulin Polymerization Promoting Protein TPPP/P25A degradation in oligodendrocytes

    F. Arvanitaki, P. Mavroeidi, M. Vetsi, S. Becker, PH. Jensen, D. Vlachakis, L. Stefanis, M. Xilouri (Athens, Greece)

    Objective: Our aim is to identify the proteolytic pathways responsible for the clearance of TPPP/P25A in oligodendrocytes, which may eventually represent potential therapeutic targets for…
  • MDS Virtual Congress 2021

    Attitudes on therapy-associated risks in individuals with multiple system atrophy and Parkinson’s disease and their views on aspects of clinical trials

    AM. Bernhardt, T. Barthel, I. Friedrich, E. Kocakavuk, E. Nachman, M. Oeller, K. Peikert, M. Roderigo, A. Rossmann, LO. Wilhelm, M. Brandt, J. Classen, BH. Falkenburger, A. Frank, L. Hoegner, H. Jacobi, A. Janzen, S. Katzdobler, J. Nieweler, T. Prell, JJ. Rumpf, C. van Riesen, T. Warnecke, M. Weiler, F. Gandor, J. Levin, A. Giese, WH. Oertel (Munich, Germany)

    Objective: To assess risk attitudes of patients suffering from multiple system atrophy (MSA) and Parkinson’s disease (PD) on future disease-modifying therapies as well as related…
  • « Previous Page
  • 1
  • …
  • 955
  • 956
  • 957
  • 958
  • 959
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley